Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Heres What You Should Know The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this…
Rapt Therapeutics (RAPT) Upgraded to Buy: Heres What You Should Know Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…
RAPT Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based…
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the…
RAPT Therapeutics stock rises following licensing deal with Jemincare By Investing.com RAPT Therapeutics stock rises following licensing deal with Jemincare…
RAPT Therapeutics Reports Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based…
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology…
RAPT Therapeutics Reports Second Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based…
Rapport Therapeutics Announces Pricing of Initial Public Offering BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology…
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients - Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status…
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…